Skip to content
Awesome – Lifestyle
Author:
Moderna, Inc.
Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate
April 29, 2026
Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna’s mRNA Combination Vaccine Against Influenza and COVID-19
April 29, 2026
Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting
April 29, 2026
Moderna to Present at Upcoming Conferences in May 2026
April 29, 2026
Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting
April 28, 2026
Moderna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026
April 15, 2026
Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026
April 7, 2026
Moderna Resolves Global Patent Litigation with Arbutus/Genevant
March 6, 2026
European Medicines Agency’s Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna’s mRNA Combination Vaccine Against Influenza and COVID-19
March 5, 2026
←
Previous Page
1
2